Skip to main content
Clinical Trials/NCT05958303
NCT05958303
Completed
Not Applicable

Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences

University of Wisconsin, Madison1 site in 1 country24 target enrollmentJuly 24, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cerebrovascular Disorders
Sponsor
University of Wisconsin, Madison
Enrollment
24
Locations
1
Primary Endpoint
Cerebral Blood Flow: Hyperoxia
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

30 participants (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy will be enrolled into this study to test the role of reactive oxygen species (ROS) in regulating cerebral blood flow (CBF). Participants can expect to be on study for 2 study visits over a 6 month period.

Detailed Description

Objective: The current objective is to determine whether biological sex influences CBF control in hyperoxia in healthy young adults without confounds of age or disease. The investigators will address 3 specific questions: 1. Are cerebral vasoconstrictor responses to hyperoxia greater in men? 2. Do all brain regions respond equally, or are there regional differences-possibly varying by sex? 3. Do ROS regulate the decrease in CBF in a sex specific fashion? This study will be conducted in compliance with federal investigational drug regulations (21 CFR 312) and Good Clinical Practice (GCP) guidelines, as well as state law and institutional policies. Study Population: This study includes 30 total participants; (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy. Approach: CBF testing will be performed in research-dedicated MRI systems on UW campus. Participants will experience normoxia followed by hyperoxia conditions during each of the 2 study visits. Study design focuses on the use of an acute oral antioxidant cocktail (AOC) to test ROS signaling as a potential mechanism explaining sex differences in CBF control. To do this, 2 MRI visits in a double-blind placebo-controlled design will be conducted.

Registry
clinicaltrials.gov
Start Date
July 24, 2024
End Date
March 31, 2025
Last Updated
8 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between ≥18 - ≤40 years

Exclusion Criteria

  • Hypertensive
  • \>125 mmHg systolic blood pressure; or
  • \>80 mmHg diastolic blood pressure
  • BMI ≥25 kg/m2
  • Fasting blood glucose ≥100 mg/dl
  • LDL cholesterol ≥130 mg/dl
  • Triglycerides ≥150 mg/dl
  • Current diagnosis or history of:
  • peripheral vascular disease
  • hepatic disease

Outcomes

Primary Outcomes

Cerebral Blood Flow: Hyperoxia

Time Frame: up to 6 months

Participants will be randomized to AOC or placebo. Hyperoxia measures will be collected under each condition in the MRI over 2 study visits.

Cerebral Blood Flow: Normoxia

Time Frame: up to 6 months

Participants will be randomized to AOC or placebo. Normoxia measures will be collected under each condition in the MRI over 2 study visits.

Study Sites (1)

Loading locations...

Similar Trials